PharmaDrug is building a European controlled substances company with a focus on Medical Cannabis and Psychedelics.
Stock Performance
Pharmadrug News 37 articles
- PharmaDrug Announces Issuance of Debenture Units
- PharmaDrug’s Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
- PharmaDrug’s Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
- PharmaDrug’s Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
- PharmaDrug’s Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
- PharmaDrug’s Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
- Pharmadrug’s Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine
- PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
- PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
- PharmaDrug Announces Director Appointment and Resignation
- PharmaDrug’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
- PharmaDrug’s SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
- PharmaDrug’s SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
- PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
- PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
- PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
- PharmaDrug CEO Provides Vision for Securedose Acquisition
- PharmaDrug Inc. Completes Debt Restructuring
- PharmaDrug Inc. Closes Acquisition of Securedose Synthetics
- PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
- PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer
- PharmaDrug Announces Amendment to Shareholder Meeting Matter
- PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease
- PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing
- PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues
- PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure
- PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma
- PharmaDrug Announces Filing of US Provisional Patent for Cepharanthine to Treat Prostate Cancer
- PharmaDrug Commences Trading on the OTCQB Market in the United States
- PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
- PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
- Pharmadrug’s Supersmart Launches Psilocybin Online Retail Platform in the Netherlands
- PharmaDrug Files For FDA Orphan Drug Designation For DMT
- PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke
- PharmaDrug Appoints DMT Expert
- PharmaDrug Positions for Eurozone Psychedelic Distribution as Germany Begins Psilocybin Depression Study
- German Cannabis Distributor Signs LOI to Acquire Dutch Psychedelic Company